1. Role: Director. Scope: Department. Date: 2019.
Grant H. Skrepnek, Ph.D., R.Ph.
Professor
Pharmacy Clinical & Admin Sci
Phone (405) 271-6878 x47105
Fax (4050 271-6430
Office CPB 214
Email grant-skrepnek@ouhsc.edu
Summary
I concentrate on health economics, policy, and outcomes research involving large-scale database investigations, decision analyses, clinical trials, and survey research. From a clinical stance, I focus on studying cost, quality, and access to care across various healthcare settings concerning oncology, cardiopulmonary disease, rare conditions, and comorbidities. I am engaged in advancing the methodological approaches used within assessments of health technology, including the development of novel statistical procedures to evaluate health and economic data.
Research
Dr. Skrepnek concentrates on health economics, policy, and outcomes research involving large-scale database investigations, decision analyses, clinical trials, and survey research. From a clinical stance, Dr. Skrepnek focuses on studying cost, quality, and access to care across various healthcare settings concerning oncology, cardiopulmonary disease, rare conditions, and comorbidities. He is engaged in advancing the methodological approaches used within assessments of health technology, including the development of novel statistical procedures to evaluate health and economic data.
Publications & Presentations
- 106. Skrepnek G H, Armstrong E P, Malone D C, Abarca J, Murphy J E, Grizzle A J, Rehfeld R A, Woosley R L. Workload and availability of technology in metropolitan community pharmacies. Journal of the American Pharmacists Association : JAPhA. 2006; 46 : 154-60
107. Skrepnek G H, Abarca J, Malone D C, Armstrong E P, Shirazi F M, Woosley R L. Incremental effects of concurrent pharmacotherapeutic regimens for heart failure on hospitalizations and costs. The Annals of pharmacotherapy. 2005; 39 : 1785-91
108. Skrepnek G H. Cost-effectiveness of HMG-CoA reductase inhibitors in the treatment of dyslipidemia and prevention of CHD. Expert review of pharmacoeconomics & outcomes research. 2005; 5 : 603-23
109. Skrepnek G H. Regression methods in the empiric analysis of health care data. Journal of managed care pharmacy : JMCP. 2005; 11 : 240-51
110. Skrepnek G H, Ballard E E. Cost-efficacy of imatinib versus allogeneic bone marrow transplantation with a matched unrelated donor in the treatment of chronic myelogenous leukemia: a decision-analytic approach. Pharmacotherapy. 2005; 25 : 325-34
Grants
- 11. Improving the Health of Americans through Prevention and Management of Diabetes, Heart Disease, and Stroke. Non-federal. Start Date: 2019. End Date: 2020.
12. Allergan (PI: Keast). Federal Non-NIH. Start Date: 2018. End Date: 2019.
13. Otsuka (Skrepnek/Keast PI). Non-federal. Start Date: 2018. End Date: 2019.
14. Research Fellowship. PhRMA. Start Date: 2017. End Date: 2018.
15. Development of a Predictive Model for METAVIR Fibrosis Scores for Patients Chronically Infected with Hepatitis C Virus. Misc Non-Federal. Start Date: 2017.
Awards and Honors
no results
Education
no results
Administrative Assignments
2. Role: Director. Scope: Department. Description: Interim Director & Director of Academic Research. Date: 2019.